CoChat

Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis*

Luckey, Marjorie, Kagan, Risa, Greenspan, Susan, Bone, Henry, Kiel, R. Douglas P., Simon, James, Sackarowitz, Jennifer, Palmisano, Joanne, Chen, Erluo, Petruschke, Richard A., de Papp, Anne E. · 2004 · Menopause
Cited by 56

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

In Brief Objective: To compare the efficacy and tolerability of once-weekly (OW) alendronate (ALN) 70 mg and raloxifene (RLX) 60 mg daily in the treatment of postmenopausal osteoporosis. Design: This 12-month, randomized, double-blind study enrolled 456 postmenopausal women with osteoporosis (223 ALN, 233 RLX) at 52 sites in the United States. Efficacy measurements included lumbar spine (LS), total hip, and trochanter bone mineral density (BMD) at 6 and 12 months, biochemical markers of bone turnover, and percent of women who maintained or gained BMD in response to treatment. The primary endpoint was percent change from baseline in LS BMD at 12 months. Adverse experiences were recorded to assess treatment safety and tolerability. Results: Over 12 months, OW ALN produced a significantly greater increase in LS BMD (4.4%, P < 0.001) than RLX (1.9%). The percentage of women with ≥ 0% increase in LS BMD (ALN, 94%; RLX, 75%; P < 0.001) and ≥ 3% increase in LS BMD (ALN, 66%; RLX, 38%; P < 0.001) were significantly greater with ALN than RLX. Total hip and trochanter BMD increases were also significantly greater (P ≤0.001) with ALN. Greater (P < 0.001) reductions in N-telopeptide of type I collagen and bone-specific alkaline phosphatase were achieved with ALN compared with RLX at 6 and 12 months. No significant differences in the incidence of upper gastrointestinal or vasomotor adverse experiences were seen. Conclusion: ALN 70 mg OW produced significantly greater increases in spine and hip BMD and greater reductions in markers of bone turnover than RLX over 12 months. A greater percentage of women maintained or gained BMD on ALN than RLX. Both medications had similar safety and tolerability profiles. In a randomized, double-blind, double-dummy, 12-month study of women with postmenopausal osteoporosis, women treated with alendronate 70 mg once weekly had significantly greater increases in spine and hip bone mineral density and greater reductions in markers of bone turnover (NTx and BSAP) than women treated with raloxifene 60 mg daily. The study medications had similar safety and tolerability profiles, with no significant differences in the incidence of upper gastrointestinal or vasomotor adverse experiences.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.gme.0000119981.77837.1f

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 56

Metadata

Authors
Luckey, M., Kagan, R., Greenspan, S., Bone, H., Kiel, R. D. P., Simon, J., Sackarowitz, J., Palmisano, J., Chen, E., Petruschke, R. A., & de Papp, A. E.
Venue
Menopause
Published
2004-07
Volume
11
Issue
4
Pages
405-415
ISSN
1072-3714 (ISSN-L)
OpenAlex
W2070769074
Cited by
56
References
7
FWCI
5.27
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis*. https://app.cochat.ai/papers/10.1097/01.gme.0000119981.77837.1f
The paper
Luckey, M., Kagan, R., Greenspan, S., Bone, H., Kiel, R. D. P., Simon, J., Sackarowitz, J., Palmisano, J., Chen, E., Petruschke, R. A., & de Papp, A. E. (2004). Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis*. Menopause. https://doi.org/10.1097/01.gme.0000119981.77837.1f

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.